Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 19, Pages 4820
Publisher
MDPI AG
Online
2021-09-27
DOI
10.3390/cancers13194820
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review
- (2021) Priyanka Singh et al. MEDICAL ONCOLOGY
- Lonafarnib: First Approval
- (2021) Sohita Dhillon DRUGS
- Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021
- (2021) Tariq I. Mughal et al. HAEMATOLOGICA
- PKC‐β/Alox5 axis activation promotes Bcr‐Abl‐independent TKI‐resistance in chronic myeloid leukemia
- (2021) Dan Ma et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
- (2021) Valentín Garcia-Gutiérrez et al. Blood Cancer Journal
- Third-line therapy for chronic myeloid leukemia: current status and future directions
- (2021) Jorge Cortes et al. Journal of Hematology & Oncology
- Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape
- (2021) Ya-Ching Hsieh et al. LEUKEMIA
- Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation
- (2021) Hui Mu et al. Frontiers in Oncology
- Relationship between Oxidative Stress and Imatinib Resistance in Model Chronic Myeloid Leukemia Cells
- (2021) Sylwester Głowacki et al. Biomolecules
- A Machine Learning Model to Successfully Predict Future Diagnosis of Chronic Myelogenous Leukemia With Retrospective Electronic Health Records Data
- (2021) Ronald G Hauser et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
- (2021) Meike Kaehler et al. Frontiers in Pharmacology
- Understanding the hematopoietic microenvironment in chronic myeloid leukemia: A concise review
- (2021) P Torres-Barrera et al. Current Research in Translational Medicine
- Treatment-Free Remission—A New Aim in the Treatment of Chronic Myeloid Leukemia
- (2021) Paulina Kwaśnik et al. Journal of Personalized Medicine
- Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making
- (2020) Simona Soverini et al. BLOOD
- Unraveling survivin expression in chronic myeloid leukemia: Molecular interactions and clinical implications
- (2020) Paula Sabbo Bernardo et al. BLOOD REVIEWS
- DNA Damage and DNA Damage Response in Chronic Myeloid Leukemia
- (2020) Popp et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance
- (2020) Zi-Yuan Nie et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
- (2020) A. Hochhaus et al. LEUKEMIA
- Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells
- (2020) Seda Baykal-Köse et al. PLoS One
- Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias
- (2020) Abhishek Maiti et al. ACTA HAEMATOLOGICA
- Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
- (2020) Elias Jabbour et al. AMERICAN JOURNAL OF HEMATOLOGY
- An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia
- (2020) Tun Kiat Ko et al. BLOOD
- Response and Resistance to BCR-ABL1-Targeted Therapies
- (2020) Theodore P. Braun et al. CANCER CELL
- Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors
- (2020) Katharina Rothe et al. Cell Stem Cell
- A phase II study of BP1001 (liposomal Grb2 antisense oligonucleotide) in patients with hematologic malignancies.
- (2020) Maro Ohanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors
- (2020) Andreas Hochhaus et al. LEUKEMIA
- Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
- (2020) Rahul Kumar et al. LEUKEMIA
- Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
- (2020) Cosimo Cumbo et al. Cancer Management and Research
- Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes
- (2020) Jan Stetka et al. Cancers
- Mining Drug-Target Associations in Cancer: Analysis of Gene Expression and Drug Activity Correlations
- (2020) Monica M. Arroyo et al. Biomolecules
- MDM2 inhibition: an important step forward in cancer therapy
- (2020) Marina Konopleva et al. LEUKEMIA
- Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
- (2020) Michael W. Deininger et al. Journal of the National Comprehensive Cancer Network
- Declaration of Bcr-Abl1 independence
- (2020) Helong Zhao et al. LEUKEMIA
- The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes
- (2020) Koji Sasaki et al. AMERICAN JOURNAL OF HEMATOLOGY
- Exosomes from Bone Marrow Microenvironment-Derived Mesenchymal Stem Cells Affect CML Cells Growth and Promote Drug Resistance to Tyrosine Kinase Inhibitors
- (2020) Xiaoyan Zhang et al. Stem Cells International
- Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?
- (2020) Simona Soverini et al. Journal of Clinical Medicine
- Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
- (2019) Fiona H Tan et al. OncoTargets and Therapy
- Impact of Additional Chromosomal Aberrations on the Disease Progression of Chronic Myelogenous Leukemia
- (2019) Ramachandran Krishna Chandran et al. Frontiers in Oncology
- Everolimus in combination with Imatinib overcomes resistance in Chronic myeloid leukaemia
- (2019) Raquel Alves et al. MEDICAL ONCOLOGY
- Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells
- (2019) Puneet Agarwal et al. Cell Stem Cell
- Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options
- (2019) Daniel Nisakar Meenakshi Sundaram et al. DRUG DISCOVERY TODAY
- Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms
- (2019) Bruno A. Cardoso et al. EXPERIMENTAL HEMATOLOGY
- PF‑114, a novel selective inhibitor of BCR‑ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells
- (2019) Ekaterina Ivanova et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA
- (2019) Justin T. Brown et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study
- (2019) Aytug Kizilors et al. Lancet Haematology
- Recommandations du France Intergroupe des leucémies myéloïdes chroniques (Fi-LMC) pour l’examen des mutations du domaine kinase de BCR-ABL1 dans la leucémie myéloïde chronique
- (2019) Jean-Michel Cayuela et al. BULLETIN DU CANCER
- SIRT1 regulates metabolism and leukemogenic potential in CML stem cells
- (2019) Ajay Abraham et al. JOURNAL OF CLINICAL INVESTIGATION
- Molecular dynamics investigation on the Asciminib resistance mechanism of I502L and V468F mutations in BCR-ABL
- (2019) Jiu-Yu Zhan et al. JOURNAL OF MOLECULAR GRAPHICS & MODELLING
- MicroRNA signature refine response prediction in CML
- (2019) Raquel Alves et al. Scientific Reports
- Targeting Translation of mRNA as a Therapeutic Strategy in Cancer
- (2019) Ipsita Pal et al. Current Hematologic Malignancy Reports
- Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations
- (2019) Michael J Reff et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
- (2019) Christopher A. Eide et al. CANCER CELL
- ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?
- (2019) Dongqing Yan et al. CLINICAL CANCER RESEARCH
- Machine learning applications in the diagnosis of leukemia: Current trends and future directions
- (2019) Haneen T. Salah et al. International Journal of Laboratory Hematology
- The interaction of tumor cells and myeloid-derived suppressor cells in chronic myelogenous leukemia
- (2019) Hui Xu et al. LEUKEMIA & LYMPHOMA
- The FoxO–Autophagy Axis in Health and Disease
- (2019) Zhiyong Cheng TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors
- (2019) Marjan Yaghmaie et al. Current Hematologic Malignancy Reports
- New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia
- (2019) Peter E. Westerweel et al. Frontiers in Oncology
- Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia
- (2019) Manon Lernoux et al. BIOCHEMICAL PHARMACOLOGY
- Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study
- (2019) Zachariah DeFilipp et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Metabolic dependencies and vulnerabilities in leukemia
- (2019) Marissa Rashkovan et al. GENES & DEVELOPMENT
- Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia
- (2019) Fabien Muselli et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors
- (2019) Xuechao Liu et al. Cell and Bioscience
- Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study
- (2019) Simona Soverini et al. BLOOD
- Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update
- (2019) Luana Bavaro et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
- (2019) Simona Soverini et al. Journal of Hematology & Oncology
- Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
- (2018) Elias Jabbour et al. AMERICAN JOURNAL OF HEMATOLOGY
- The SLC22 Transporter Family: A Paradigm for the Impact of Drug Transporters on Metabolic Pathways, Signaling, and Disease
- (2018) Sanjay K. Nigam Annual Review of Pharmacology and Toxicology
- Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high risk disease
- (2018) Susan Branford et al. BLOOD
- Effect of ABCG2 , OCT1 , and ABCB1 ( MDR1 ) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial
- (2018) Sébastien Rinaldetti et al. Clinical Lymphoma Myeloma & Leukemia
- Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium
- (2018) Sook Wah Yee et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Venetoclax: A new wave in hematooncology
- (2018) Jana Mihalyova et al. EXPERIMENTAL HEMATOLOGY
- The bone marrow microenvironment in health and disease at a glance
- (2018) Rahul Kumar et al. JOURNAL OF CELL SCIENCE
- Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
- (2018) Federico Rossari et al. Journal of Hematology & Oncology
- Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML
- (2018) Oscar Brück et al. LEUKEMIA
- Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
- (2018) Michele Massimino et al. Molecular Cancer
- Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
- (2018) Simona Soverini et al. Molecular Cancer
- Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia
- (2018) Raquel Maia et al. MOLECULES
- ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells
- (2018) Laura N. Eadie et al. PLoS One
- A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia
- (2018) Su-In Lee et al. Nature Communications
- The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro
- (2018) Laura N. Eadie et al. Oncotarget
- Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment
- (2018) Elena Arrigoni et al. Stem Cells Translational Medicine
- Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial
- (2018) Maro Ohanian et al. Lancet Haematology
- Development, function and clinical significance of plasmacytoid dendritic cells in chronic myeloid leukemia
- (2018) Sabrina Inselmann et al. CANCER RESEARCH
- Polymorphisms of the multidrug pump ABCG2: a systematic review of their effect on protein expression, function and drug pharmacokinetics
- (2018) Niall Heyes et al. DRUG METABOLISM AND DISPOSITION
- BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia
- (2018) Klara Srutova et al. HAEMATOLOGICA
- Genetic variations in influx transporter gene SLC22A1 are associated with clinical responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patients
- (2018) Siti Maziras Makhtar et al. JOURNAL OF GENETICS
- Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
- (2018) Joseph Schoepfer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting quiescent leukemic stem cells using second generation autophagy inhibitors
- (2018) Pablo Baquero et al. LEUKEMIA
- Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors
- (2018) Jorge Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy
- (2018) Tatjana Bilich et al. BLOOD
- Nilotinib in the treatment of chronic myeloid leukemia
- (2018) Tomasz Sacha et al. Future Oncology
- A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease
- (2018) Kendra Sweet et al. LEUKEMIA RESEARCH
- Chronic myeloid leukemia: Existing therapeutic options and strategies to overcome drug resistance
- (2018) Vivek Kumar Singh et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents
- (2017) Giovanni Luca Beretta et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors
- (2017) Ami B. Patel et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Epigenetic dysregulation of hematopoietic stem cells and preleukemic state
- (2017) Hiroyoshi Kunimoto et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Chemokines as a Conductor of Bone Marrow Microenvironment in Chronic Myeloid Leukemia
- (2017) Naofumi Mukaida et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia
- (2017) Ziyuan Lu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Combined inhibition of β-catenin and Bcr–Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo
- (2017) H Zhou et al. LEUKEMIA
- Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia
- (2017) Ayuna Hattori et al. NATURE
- The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
- (2017) Andrew A. Wylie et al. NATURE
- Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells
- (2017) Elodie M Kuntz et al. NATURE MEDICINE
- Remembrance of things past — discontinuation of second-generation TKI therapy for CML
- (2017) Timothy P. Hughes et al. Nature Reviews Clinical Oncology
- Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis
- (2017) Zhi-Ping Jiang et al. PHARMACOGENOMICS
- Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia
- (2017) E Togasaki et al. Blood Cancer Journal
- Intelligent Techniques Using Molecular Data Analysis in Leukaemia: An Opportunity for Personalized Medicine Support System
- (2017) Haneen Banjar et al. Biomed Research International
- Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission
- (2017) Amy Hughes et al. Frontiers in Immunology
- Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring
- (2016) Elias Jabbour et al. AMERICAN JOURNAL OF HEMATOLOGY
- The C421A (Q141K) polymorphism enhances the 3′-untranslated region (3′-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2
- (2016) Anne Ripperger et al. BIOCHEMICAL PHARMACOLOGY
- Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy
- (2016) TaeHyung Kim et al. BLOOD
- Somatic mosaicism in chronic myeloid leukemia in remission
- (2016) K. Mitani et al. BLOOD
- Moving treatment-free remission into mainstream clinical practice in CML
- (2016) Timothy P. Hughes et al. BLOOD
- Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study
- (2016) Philippe Rousselot et al. CANCER
- miR-146b-5p within BCR-ABL1-Positive Microvesicles Promotes Leukemic Transformation of Hematopoietic Cells
- (2016) H.-M. Zhang et al. CANCER RESEARCH
- ABC transporters as mediators of drug resistance and contributors to cancer cell biology
- (2016) Jamie I. Fletcher et al. DRUG RESISTANCE UPDATES
- Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications
- (2016) Lisa Pleyer et al. Journal of Hematology & Oncology
- A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia
- (2016) M Wagle et al. LEUKEMIA
- The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment
- (2016) L N Eadie et al. LEUKEMIA
- Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia
- (2016) Juan Eduardo Megías-Vericat et al. LEUKEMIA & LYMPHOMA
- Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1 35INS
- (2016) Ellin Berman et al. LEUKEMIA RESEARCH
- Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice
- (2016) Flavia da Cunha Vasconcelos et al. LEUKEMIA RESEARCH
- MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells
- (2016) Tsung-Yao Lin et al. PLoS One
- Depleting dietary valine permits nonmyeloablative mouse hematopoietic stem cell transplantation
- (2016) Y. Taya et al. SCIENCE
- Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors
- (2016) Claudia Neul et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients
- (2016) S Harrach et al. Blood Cancer Journal
- MicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia
- (2016) Chiranjib Chakraborty et al. Oncotarget
- Identification and functional characterization of the miRNA-gene regulatory network in chronic myeloid leukemia lineage negative cells
- (2016) S. Agatheeswaran et al. Scientific Reports
- Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia
- (2016) David A. Irvine et al. Scientific Reports
- Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
- (2016) Lauren Caldemeyer et al. Current Hematologic Malignancy Reports
- ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines
- (2016) Laura N. Eadie et al. PLoS One
- Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors
- (2015) W. Wang et al. BLOOD
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- The dynamics of adult haematopoiesis in the bone and bone marrow environment
- (2015) Miriel S. H. Ho et al. BRITISH JOURNAL OF HAEMATOLOGY
- Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia
- (2015) Shantashri Vaidya et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML)
- (2015) Silvia Marcé et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia
- (2015) Fatima Dkhissi et al. EXPERIMENTAL HEMATOLOGY
- Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
- (2015) Marialuisa Polillo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- OCT1 and imatinib transport in CML: is it clinically relevant?
- (2015) D B Watkins et al. LEUKEMIA
- Drug transporters play a key role in the complex process of Imatinib resistance in vitro
- (2015) Raquel Alves et al. LEUKEMIA RESEARCH
- Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms
- (2015) Gregor Hoermann et al. MEDIATORS OF INFLAMMATION
- Structure and function of Gab2 and its role in cancer (Review)
- (2015) CHEN-BO DING et al. Molecular Medicine Reports
- Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists
- (2015) Stéphane Prost et al. NATURE
- Dipeptide species regulate p38MAPK–Smad3 signalling to maintain chronic myelogenous leukaemia stem cells
- (2015) Kazuhito Naka et al. Nature Communications
- The physiological role of drug transporters
- (2015) Yu Liang et al. Protein & Cell
- Evolution of BCR/ABL Gene Mutation in CML Is Time Dependent and Dependent on the Pressure Exerted by Tyrosine Kinase Inhibitor
- (2015) Shantashri Vaidya et al. PLoS One
- MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways
- (2015) Anne Y. Saiki et al. Oncotarget
- Epigenetic drugs against cancer: an evolving landscape
- (2014) Antonella Di Costanzo et al. ARCHIVES OF TOXICOLOGY
- Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients
- (2014) Anthony Au et al. BIOMEDICINE & PHARMACOTHERAPY
- ApoptomiRs expression modulated by BCR–ABL is linked to CML progression and imatinib resistance
- (2014) A.F. Ferreira et al. BLOOD CELLS MOLECULES AND DISEASES
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
- (2014) Matthew S. Zabriskie et al. CANCER CELL
- Structure, Function, and Resistance in Chronic Myeloid Leukemia
- (2014) Jerald Radich CANCER CELL
- Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation
- (2014) Paulina Podszywalow-Bartnicka et al. CELL CYCLE
- Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia
- (2014) V. Gandhi et al. CLINICAL CANCER RESEARCH
- Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy
- (2014) S. Bibi et al. HAEMATOLOGICA
- Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival
- (2014) Yaoyu Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells
- (2014) M Nieborowska-Skorska et al. LEUKEMIA
- PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation
- (2014) A A Mian et al. LEUKEMIA
- Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status
- (2014) M Schmidt et al. LEUKEMIA
- Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia
- (2014) Luciene Terezina de Lima et al. MEDICAL ONCOLOGY
- A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia
- (2014) L. Ma et al. Science Translational Medicine
- Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors
- (2013) J. Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile
- (2013) K. Cramer-Morales et al. BLOOD
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
- (2013) A. Hochhaus et al. BLOOD
- JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia
- (2013) W. Warsch et al. BLOOD
- Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt- -catenin signaling
- (2013) B. Zhang et al. BLOOD
- Myeloproliferative Neoplasia Remodels the Endosteal Bone Marrow Niche into a Self-Reinforcing Leukemic Niche
- (2013) Koen Schepers et al. Cell Stem Cell
- Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib
- (2013) L N Eadie et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
- (2013) Simona Soverini et al. LEUKEMIA RESEARCH
- Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
- (2013) Lisa Christiansson et al. PLoS One
- Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation
- (2013) M Sigl et al. Blood Cancer Journal
- Signal Transduction in the Chronic Leukemias: Implications for Targeted Therapies
- (2013) Wesam Ahmed et al. Current Hematologic Malignancy Reports
- Role of Epigenetics in Chronic Myeloid Leukemia
- (2013) Katerina Machova Polakova et al. Current Hematologic Malignancy Reports
- Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors
- (2012) Sara Redaelli et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
- (2012) J. Cortes et al. BLOOD
- HIF1 is required for survival maintenance of chronic myeloid leukemia stem cells
- (2012) H. Zhang et al. BLOOD
- Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
- (2012) Xuelin Huang et al. CANCER
- Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML
- (2012) Florian H. Heidel et al. Cell Stem Cell
- Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up
- (2012) Sagar Agarwal et al. CURRENT PHARMACEUTICAL DESIGN
- Bone Marrow Microenvironment in Multiple Myeloma Progression
- (2012) S. Manier et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability
- (2012) A Slupianek et al. LEUKEMIA
- Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors
- (2012) F U Wöhrle et al. LEUKEMIA
- DNA damage response in imatinib resistant chronic myeloid leukemia K562 cells
- (2012) Joana Dinis et al. LEUKEMIA & LYMPHOMA
- Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia
- (2012) Ellen K. Ritchie et al. LEUKEMIA & LYMPHOMA
- Autophagy modulation as a potential therapeutic target for diverse diseases
- (2012) David C. Rubinsztein et al. NATURE REVIEWS DRUG DISCOVERY
- Sirtuins as regulators of metabolism and healthspan
- (2012) Riekelt H. Houtkooper et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias
- (2012) L A Tobin et al. ONCOGENE
- Genetic Mechanisms of Chronic Myeloid Leukemia Blastic Transformation
- (2012) Tomasz Skorski Current Hematologic Malignancy Reports
- Role of STAT3 in Transformation and Drug Resistance in CML
- (2012) Rajesh R. Nair et al. Frontiers in Oncology
- Drug Transporters in Drug Efficacy and Toxicity
- (2011) M.K. DeGorter et al. Annual Review of Pharmacology and Toxicology
- Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
- (2011) A. Fabarius et al. BLOOD
- BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
- (2011) S. Soverini et al. BLOOD
- High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia
- (2011) W. Warsch et al. BLOOD
- Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
- (2011) J. E. Cortes et al. BLOOD
- Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
- (2011) H. M. Kantarjian et al. BLOOD
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Epigenetic inactivation of the hsa-miR-203 in haematological malignancies
- (2011) Chor Sang Chim et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells
- (2011) Peter P. Ruvolo et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance
- (2011) Hilmar Quentmeier et al. Journal of Hematology & Oncology
- A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases
- (2011) V Grossmann et al. LEUKEMIA
- Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state
- (2011) Tomasz Skorski LEUKEMIA & LYMPHOMA
- Mechanisms of resistance to BCR–ABL kinase inhibitors
- (2011) Joana M. Diamond et al. LEUKEMIA & LYMPHOMA
- Expression patterns of microRNAs associated with CML phases and their disease related targets
- (2011) Kateřina Machová Poláková et al. Molecular Cancer
- Establishment of a standardized multiplex assay with the analytical performance required for quantitative measurement of BCR–ABL1 on the international reporting scale
- (2011) J T Brown et al. Blood Cancer Journal
- MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML
- (2011) Sukanya Suresh et al. Journal of Cell Communication and Signaling
- BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib
- (2010) D. W. Sherbenou et al. BLOOD
- BCR-ABL stimulates mutagenic homologous DNA double-strand break repair via the DNA-end-processing factor CtIP
- (2010) Daniela Salles et al. CARCINOGENESIS
- Immunotherapy of chronic myeloid leukemia: present state and future prospects
- (2010) Vladimír Vonka Immunotherapy
- Deactylase inhibition in myeloproliferative neoplasms
- (2010) Sridurga Mithraprabhu et al. INVESTIGATIONAL NEW DRUGS
- Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group
- (2010) Torsten Haferlach et al. JOURNAL OF CLINICAL ONCOLOGY
- Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
- (2010) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- Exploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribed
- (2010) Lina Eliasson et al. LEUKEMIA RESEARCH
- A Genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers
- (2010) Thomas Dunwell et al. Molecular Cancer
- Expression of Oncogenic Kinase Bcr-Abl Impairs Mitotic Checkpoint and Promotes Aberrant Divisions and Resistance to Microtubule-Targeting Agents
- (2010) K. Wolanin et al. MOLECULAR CANCER THERAPEUTICS
- TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
- (2010) Kazuhito Naka et al. NATURE
- Dasatinib in chronic myeloid leukemia: a review
- (2010) Apostolia-Maria Tsimberidou Therapeutics and Clinical Risk Management
- Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
- (2009) L. Noens et al. BLOOD
- Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression
- (2009) S. Mumprecht et al. BLOOD
- Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties
- (2009) C Hegedűs et al. BRITISH JOURNAL OF PHARMACOLOGY
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia
- (2009) D. H. Kim et al. CLINICAL CANCER RESEARCH
- Akt-mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt
- (2009) Dong Bai et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells
- (2009) Cristian Bellodi et al. JOURNAL OF CLINICAL INVESTIGATION
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- Methylation status of RASSF1A in patients with chronic myeloid leukemia
- (2009) Antigoni Avramouli et al. LEUKEMIA RESEARCH
- A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia
- (2009) Hugues de Lavallade et al. LEUKEMIA RESEARCH
- Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia
- (2009) Yaoyu Chen et al. NATURE GENETICS
- Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia
- (2008) A. Giannoudis et al. BLOOD
- Genomic instability in myeloid malignancies: Increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair
- (2008) Annahita Sallmyr et al. CANCER LETTERS
- BCR/ABL and Other Kinases from Chronic Myeloproliferative Disorders Stimulate Single-Strand Annealing, an Unfaithful DNA Double-Strand Break Repair
- (2008) K. Cramer et al. CANCER RESEARCH
- Interaction of Imatinib with Human Organic Ion Carriers
- (2008) S. Hu et al. CLINICAL CANCER RESEARCH
- Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications
- (2008) D. K. Hiwase et al. CLINICAL CANCER RESEARCH
- The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance
- (2008) M. B. Meads et al. CLINICAL CANCER RESEARCH
- P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia
- (2008) Shundong Cang et al. Journal of Hematology & Oncology
- Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia
- (2008) Shaoguang Li LEUKEMIA & LYMPHOMA
- Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance
- (2008) Nadine N. Bewry et al. MOLECULAR CANCER THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started